Co-funded expanded access programmes for new oncology drugs: Creating a two-tier system for Australian cancer patients?

Internal Medicine Journal

Volumn 43, Issue 7, 2013, Pages 843-844

  Azad, A ^a   Franco, M ^b,c  

^a AUSTIN HEALTH   (Australia)

^b Melbourne Children's Sleep Centre   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; CETUXIMAB; FULVESTRANT; TEMSIROLIMUS;

ADVANCED CANCER; AUSTRALIA; BREAST CANCER; CANCER PATIENT; COLORECTAL CANCER; COMPASSIONATE USE; DRUG INDUSTRY; HUMAN; KIDNEY CANCER; LETTER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HOSPITAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMPASSIONATE USE TRIALS; FEMALE; HUMANS; MALE;

EID: 84880394566     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12126     Document Type: Letter

References (4)

1. Tie J, Gibbs P. Treatment with unfunded drugs in oncology: the impact of access programmes and clinical trials. Intern Med J 2013; 43: 23-31.
2. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L etal. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC etal. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
4. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A etal. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.